Targeting CXCR4 with CTCE-9908 inhibits prostate tumor metastasis

BMC Urology

Volumn 14, Issue 1, 2014, Pages

  Wong, Donald ^c   Kandagatla, Pridvi ^a   Korz, Walter ^c   Chinni, Sreenivasa R ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

^c British Canadian BioSciences Corporation   (Canada)

Author keywords

Chemoinvasion and prostate cancer progression; CTCE 9908; CXCL12; CXCR4

Indexed keywords

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; MALE; MOLECULAR TARGETED THERAPY; PEPTIDES; PROSTATIC NEOPLASMS; RECEPTORS, CXCR4; TREATMENT OUTCOME;

EID: 84892949720     PISSN: None     EISSN: 14712490     Source Type: Journal    
DOI: 10.1186/1471-2490-14-12     Document Type: Article

References (28)

1. Cancer and the chemokine network. Balkwill F, Nat Rev Cancer 2004 4 7 540 550 10.1038/nrc1388 15229479 (Pubitemid 38868623)
2. Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. Sun YX, Wang J, Shelburne CE, Lopatin DE, Chinnaiyan AM, Rubin MA, Pienta KJ, Taichman RS, J Cell Biochem 2003 89 3 462 473 10.1002/jcb.10522 12761880 (Pubitemid 36648768)
3. Tumor immunobiological differences in prostate cancer between African-American and European-American men. Wallace TA, Prueitt RL, Yi M, Howe TM, Gillespie JW, Yfantis HG, Stephens RM, Caporaso NE, Loffredo CA, Ambs S, Cancer Res 2008 68 3 927 936 10.1158/0008-5472.CAN-07-2608 18245496 (Pubitemid 351206772)
4. Chemokine receptor CXCR4 expression and prognosis in patients with metastatic prostate cancer. Akashi T, Koizumi K, Tsuneyama K, Saiki I, Takano Y, Fuse H, Cancer Sci 2008 99 3 539 542 10.1111/j.1349-7006.2007.00712.x 18201276 (Pubitemid 351228571)
5. CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12. Chinni SR, Sivalogan S, Dong Z, Filho JC, Deng X, Bonfil RD, Cher ML, Prostate 2006 66 1 32 48 10.1002/pros.20318 16114056 (Pubitemid 43005947)
6. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK, Cancer Res 2002 62 6 1832 1837 11912162 (Pubitemid 34408510)
7. The importance of the CXCL12-CXCR4 chemokine ligand-receptor interaction in prostate cancer metastasis. Arya M, Patel HR, McGurk C, Tatoud R, Klocker H, Masters J, Williamson M, J Exp Ther Oncol 2004 4 4 291 303 15844659 (Pubitemid 40189442)
8. Up-regulation of CXCR4 expression in PC-3 cells by stromal-derived factor-1alpha (CXCL12) increases endothelial adhesion and transendothelial migration: role of MEK/ERK signaling pathway-dependent NF-kappaB activation. Kukreja P, Abdel-Mageed AB, Mondal D, Liu K, Agrawal KC, Cancer Res 2005 65 21 9891 9898 10.1158/0008-5472.CAN-05-1293 16267013 (Pubitemid 41541469)
9. CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion. Singh S, Singh UP, Grizzle WE, Lillard JW Jr, Lab Invest 2004 84 12 1666 1676 10.1038/labinvest.3700181 15467730 (Pubitemid 39600573)
10. CXCL12/CXCR4 Transactivates HER2 in Lipid Rafts of Prostate Cancer Cells and Promotes Growth of Metastatic Deposits in Bone. Chinni SR, Yamamoto H, Dong Z, Sabbota A, Bonfil RD, Cher ML, Molecular cancer research: MCR 2008 6 3 446 457 10.1158/1541-7786.MCR-07-0117 18337451 (Pubitemid 351416535)
11. Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. Darash-Yahana M, Pikarsky E, Abramovitch R, Zeira E, Pal B, Karplus R, Beider K, Avniel S, Kasem S, Galun E, et al. Faseb J 2004 18 11 1240 1242 15180966 (Pubitemid 39561563)
12. CXCR4 and CXCL12 (SDF-1) in prostate cancer: inhibitory effects of human single chain Fv antibodies. Vaday GG, Hua SB, Peehl DM, Pauling MH, Lin YH, Zhu L, Lawrence DM, Foda HD, Zucker S, Clin Cancer Res 2004 10 16 5630 5639 10.1158/1078-0432.CCR-03-0633 15328206 (Pubitemid 39100505)
13. Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. Sun YX, Schneider A, Jung Y, Wang J, Dai J, Cook K, Osman NI, Koh-Paige AJ, Shim H, Pienta KJ, et al. J Bone Miner Res 2005 20 2 318 329 15647826
14. Matrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissue. Dong Z, Bonfil RD, Chinni S, Deng X, Trindade Filho JC, Bernardo M, Vaishampayan U, Che M, Sloane BF, Sheng S, et al. Am J Pathol 2005 166 4 1173 1186 10.1016/S0002-9440(10)62337-1 15793297 (Pubitemid 40524441)
15. CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression. Sun X, Cheng G, Hao M, Zheng J, Zhou X, Zhang J, Taichman RS, Pienta KJ, Wang J, Cancer Metastasis Rev 2011 29 4 709 722
16. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E, Nademanee A, McCarty J, Bridger G, Calandra G, J Clin Oncol 2009 27 28 4767 4773 10.1200/JCO.2008.20. 7209 19720922
17. CXCR4 chemokine receptor antagonists: perspectives in SCLC. Burger JA, Stewart DJ, Expert Opin Investig Drugs 2009 18 4 481 490 10.1517/ 13543780902804249 19335276
18. Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Kim SY, Lee CH, Midura BV, Yeung C, Mendoza A, Hong SH, Ren L, Wong D, Korz W, Merzouk A, et al. Clin Exp Metastasis 2008 25 3 201 211 10.1007/s10585-007-9133-3 18071913
19. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Rubin JB, Kung AL, Klein RS, Chan JA, Sun Y, Schmidt K, Kieran MW, Luster AD, Segal RA, Proc Natl Acad Sci USA 2003 100 23 13513 13518 10.1073/pnas.2235846100 14595012 (Pubitemid 37444773)
20. Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma. Kajiyama H, Shibata K, Terauchi M, Ino K, Nawa A, Kikkawa F, Int J Cancer 2008 122 1 91 99 10.1002/ijc.23083 17893878 (Pubitemid 350209982)
21. A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. Huang EH, Singh B, Cristofanilli M, Gelovani J, Wei C, Vincent L, Cook KR, Lucci A, J Surg Res 2009 155 2 231 236 10.1016/j.jss.2008. 06.044 19482312
22. Effects of CXCR4 antagonist CTCE-9908 on prostate tumor growth. Porvasnik S, Sakamoto N, Kusmartsev S, Eruslanov E, Kim WJ, Cao W, Urbanek C, Wong D, Goodison S, Rosser CJ, Prostate 2009 69 13 1460 1469 10.1002/pros.21008 19588526
23. Viable circulating metastatic cells produced in orthotopic but not ectopic prostate cancer models. Glinskii AB, Smith BA, Jiang P, Li XM, Yang M, Hoffman RM, Glinsky GV, Cancer Res 2003 63 14 4239 4243 12874032 (Pubitemid 36917952)
24. Inhibition of human prostate cancer growth, osteolysis and angiogenesis in a bone metastasis model by a novel mechanism-based selective gelatinase inhibitor. Bonfil RD, Sabbota A, Nabha S, Bernardo MM, Dong Z, Meng H, Yamamoto H, Chinni SR, Lim IT, Chang M, et al. Int J Cancer 2006 118 11 2721 2726 10.1002/ijc.21645 16381009 (Pubitemid 43673349)
25. Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone. Richert MM, Vaidya KS, Mills CN, Wong D, Korz W, Hurst DR, Welch DR, Oncol Rep 2009 21 3 761 767 19212637
26. Residual prostate cancer cells after docetaxel therapy increase the tumorigenic potential via constitutive signaling of CXCR4, ERK1/2 and c-Myc. Hatano K, Yamaguchi S, Nimura K, Murakami K, Nagahara A, Fujita K, Uemura M, Nakai Y, Tsuchiya M, Nakayama M, et al. Molecular cancer research: MCR 2013 11 9 1088 1100 10.1158/1541-7786.MCR-13-0029-T 23788635
27. CXCR4 expression in prostate cancer progenitor cells. Dubrovska A, Elliott J, Salamone RJ, Telegeev GD, Stakhovsky AE, Schepotin IB, Yan F, Wang Y, Bouchez LC, Kularatne SA, et al. PLoS One 2012 7 2 31226 10.1371/journal.pone. 0031226 22359577
28. Diverse signaling pathways through the SDF-1/CXCR4 chemokine axis in prostate cancer cell lines leads to altered patterns of cytokine secretion and angiogenesis. Wang J, Sun Y, Song W, Nor JE, Wang CY, Taichman RS, Cell Signal 2005 17 12 1578 1592 10.1016/j.cellsig.2005.03.022 16005185 (Pubitemid 41253997)